ATF2

Across TCGA pan-cancer cohorts, ATF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATF2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where ATF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.394	0.864	.014	15	view →
UCEC	OS	Tertile	All	0.862	1.000	.017	6	view →
LUAD	DFS	Tertile	All	0.905	0.567	.037	2	view →
LSCC	DFS	Quartile	III,IV	0.774	1.000	.043	1	view →
PDAC	OS	Quartile	II,III,IV	0.325	0.556	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATF2–CCRCC (DFS)

Open the CCRCC breakdown →